Alphabet and Merck Group could exit the immunological and inflammatory disease therapy developer in an offering with an $86.3m placeholder target.

Carlyle Group has agreed to pay $435m for the biologics research technology provider, which has raised $86m from investors including Novo.

China Medical System and a WuXi Biologics industry investment fund were among the participants in the antibody therapy developer's $69.3m series A round.

Based on research at MIT, LiquiGlide has brought its overall funding to $50m following a $13.5m round.

University of Pennsylvania is working on a treatment for solid tumours and its only known investor is HLB Pharmaceutical.

Limited partners include drugs maker Pfizer, and healthcare-focused JSR Group and Lonza.

Vehicle charging technology developer Virta has closed an Eneos-backed round at $36m while Hubert Burda-backed wealth manager StashAway pushed its total funding past $60m.

3M-backed CNS disorder therapy developer Impel priced its initial public offering in the middle of its range, giving it a $290m market cap.

SenseTime and Sinopharm Capital have contributed to the oncology surgical device developer’s latest round, which will fund sales, marketing, product and technology improvement.

Deerfield Management has added Empire Discovery Institute to its ever-growing roster of partners for its drug discovery engine.